This work reports on the variation in wastewater treatment works (WwTW) influent concentrations of 21 a wide variety of active pharmaceutical ingredients (APIs), their removal efficiency, effluent 22 concentrations and potential risks to the aquatic environment. The research is based on data generated 23 from two large UK-wide WwTW monitoring programmes. Taking account of removal of parent 24 compound from the aqueous phase during treatment in combination with estimates of dilution 25 available it is possible to prioritise the APIs of greatest risk of exceeding estimates of predicted no 26 effect concentrations (PNEC) in receiving waters for all WwTW in the UK. The majority of 27 substances studied were removed to a high degree, although with significant variation, both within 28 and between WwTW. Poorer removal (between influent and effluent) was observed for 29 ethinyloestradiol, diclofenac, propranolol, the macrolide antibiotics, fluoxetine, tamoxifen and 30 carbamazepine. All except the last two of these substances were present in effluents at concentrations 31 higher than their respective estimated PNEC (based on measurement of effluents from 45 WwTW on 32
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13% of all WwTW) may cause exceedances of estimated riverine PNECs after mixing of their 34 effluents with receiving waters. The overall degree of risk is driven by the toxicity value selected, 35 which in itself is controlled by the availability of reliable and relevant ecotoxicological data and 36 INTRODUCTION 45 
46
The use and environmental prevalence of pharmaceuticals increases on an annual basis due to a 47 variety of reasons including the widening array of medical treatments available, greater availability of 48 medicines across the world, affordability, population growth, population ageing (in some countries) 49 and changing perspectives towards, for example, pain (Jelic et al., 2011) . Active Pharmaceutical 50 APIs in the river environment is from human use of pharmaceuticals, via the continuous discharge of 57 effluent from the Wastewater Treatment Works (WwTW) (Gardner et al., 2012; Melvin et al., 2016) . 58
Hence, investigating the occurrence, fate and risk of APIs is currently of great interest to regulators 59 and the water industry alike, with a focus to better understand the loadings entering WwTW and the 60 observed within and between works variation in removal efficiencies and concentrations often 61 observed for APIs (Gardner, 2013) . 62
63
The range of concentrations found for pharmaceuticals studied in the UK is similar to that observed in 64 Table 1 provides examples of other reported data for APIs 66 determined as part of this research, rather than a complete list of all APIs detected in effluent and 67 receiving waters. Other studies have also shown that there is a clear association between the number 68 of pharmaceuticals used in a society and the levels of API found in receiving water bodies ranging 69 from API concentration of typically less than 100 ng/l in the surface and groundwater and below 50 70 ng/l in treated drinking water (WHO, 2011; Furlong et al., 2017) to higher levels reported adjacent to 71 production facilities (Phillips et al., 2010) . Predicted no effect concentrations (PNECs) have been 72
reported for some APIs below 1 ng/l and APIs such as diclofenac (CAS 15307-79-6), 17-betaestradiol (E2) (CAS 50-28-2) and 17-alpha-ethinylestradiol (EE2) (CAS 57-63-6) are on the European 74 Water Framework Directive (WFD) 'watch list' (EU, 2013) . This requires member states to gather 75 monitoring data in order to assess risk to the environment, leading to significant sources of APIs 76 needing to be quantified and factors controlling the discharge of APIs carefully considered along with 77 impacts on receiving water ecology, including effects of mixtures (Bound and Voulvoulis, 2006 of WwTW monitored and the number of determinands in order to in some cases measure (for WFD 100 priority substances and priority hazardous substances) and in some cases predict (for emergingchemicals such as APIs) the impact on receiving waters. The CIP2 determinands include 19 APIs and 102 4 metabolites at currently 45 WwTW on 20 occasions. In total, over 60 000 samples are to be taken, 103 with over 2 million determinations. This study reports on the findings for APIs from the CIP1 and 104
CIP2 programmes. 105 106
WwTWs are primarily designed to serve the purpose of removing pathogens, suspended solids and 107 gross organic and inorganic matter, rather than the removal of the increasing numbers of modern 108 chemicals generally present in the µg/l range or less (Melvin, 2016) . It has also been observed that 109
there is a wide variation in removal rates for different substances, both within and between WwTWs. 110
This difference in removal rate creates large uncertainty factors for the prediction and modeling of 111 effluent concentrations and therefore creates a challenge in conducting meaningful risk assessments. 112
There are currently no statutory consents applied to APIs in WwTW effluent, however, there is an 113 urgent need to better understand the risk posed by APIs in effluents to receiving waters in order to 114 inform future investment and to design and implement better risk assessment (Gardner, 2013) . 
MATERIALS AND METHODS

130
Selection of Pharmaceuticals
131
The selection of chemicals for CIP1 is discussed elsewhere (Gardner et al., 2012) . The list of 132 candidate APIs for inclusion in CIP2 was based primarily on a prioritization study undertaken by 133 UKWIR in 2014 (UKWIR, 2014). Unlike many previous prioritisations, which focused on usage and 134 concentrations detected in surface waters/effluents, problem sites or substances, this study adopted a 135 risk assessment approach by comparing the estimated environmental concentrations of nearly 150 136 pharmaceuticals (screened on usage and perceived hazard from a list of thousands of candidate 137 substances) with data for their respective effect concentrations on a variety of receptor organisms in 138 the aquatic environment. 139
140
For the purposes of CIP2, this list was further refined by selection of substances that were considered 141 to have the greatest potential as candidate WFD priority substances. The criteria for this selection 142 were a) that the risk characterisation ratio (predicted concentration divided by the highest probable no 143 effect concentration (PEC/PNEC) ranked higher than 1 in the overall 2014 UKWIR prioritisation and 144 b) that the data supporting the derivation of a PNEC were relatively reliable and complied with the 145 WFD approach to PNEC derivation (EU 2011). In effect, this meant that PNECs were derived using 146 experimental rather than modelled effects, long-term effects in organisms from different trophic levels 147 were available (though short term exposure was also considered) and assessment factors were applied 148 according to WFD guidance (EU 2011). 149
150
The APIs prioritised were then further reviewed for their relevance to wastewater treatment, and the 151 likelihood that the substance might be present in sewage effluents and hence discharged to surface 152 waters (rather than being partitioned to sewage sludge). This resulted in the list of substances 153 tabulated in Table A1 these sources, the ecotoxicology data applied in deriving the PNECs reported by UKWIR (UKWIR 159 2014) were used to deterministically estimate PNECs, according to WFD guidance (EU 2011) ( Table  160 2 and ESI Table A1 ). It is recognized that as new ecotoxicity data becomes available, substance 161
PNECs are subject to update, and the estimates of PNECs applied in the present study may not, in 162 every case, reflect the most up to date applied or proposed PNEC for regulatory purposes (e.g. under 163
the WFD or European Medicines Agency (EMA) Environmental Risk Assessments. However, the 164 estimated PNECs reported here were applied in the CIP for the purposes of selection for monitoring, 165 preliminary risk assessment and prioritization, and so remain relevant in this context, and it is beyond 166 the objectives of the present study to derive new PNECs for each of the APIs monitored. 
Data handling and analysis
228
The data handling and the statistical analysis were conducted with either Microsoft Excel (2016) or 229
IBM SPSS Statistics software (version 20). 230
In the data handling, the replicates were averaged and this value was then used for further statistical 232 calculations. Mean, median, maximum, minimum and percentiles were calculated from the daily 233 
Face value risk ranking 246
A "face value" exceedance is one in which the mean effluent concentration is greater than the relevant 247 estimated PNEC; a "high confidence" exceedance is one for which the lower part of the 90% 248 confidence interval about the mean effluent concentration is greater than the estimated PNEC i.e. 249 there is 95% confidence that the mean is larger than the estimated PNEC. The next step was to generate a cumulative percentile distribution of effluent concentration data (in 266 10%ile intervals between 10 and 100%). This was achieved by averaging the effluent concentrations 267 for each of the 45 WwTW sampled as part of the CIP2 survey.
Step three was to divide each 268 percentile concentration by the dilution available (using the value from the combined distribution 269 estimate -See A3 of the ESI) to generate a PEC. The PEC can then be compared with estimated API 270
PNECs to determine the number of WwTW at risk of exceeding the PNEC for any given each dilution 271 band and percentile effluent concentration. An example of the risk assessment is provided in Table  272 A4 of the ESI. 273 274
RESULTS and DISCUSSION
275 276
Removal efficiency for APIs
278
The CIP1 study generated removal data for APIs across all stages of treatment, influent, after primary 279 settlement, secondary biological treatment and where applied, post tertiary treatment. To gain a better 280 understand of the fate of the 11 pharmaceuticals through the treatment train, the fraction of API 281 remaining in the effluent after treatment was calculated across all 25 WwTW in the CIP1 program 282 (Table 4) . 283
284
Each cycle of sampling was treated as an isolated entity (averaging the samples within the same day), 285 thus simplify the ability to compare APIs removal across the diverse range of works. As seen from thedata in Table 4 , most APIs are removed in the secondary biological treatment process and very little 287 through further tertiary treatment. This corresponds well with previously published data (Stockholm 288
Vatten, 2010). The absolute effluent concentrations (Table 4 ) also correspond well with those reported 289 elsewhere for predominantly UK effluents (Table 1) . 290 291 ERMY, DCF, FLXT and OXTCY were all shown to have similar removal efficiencies throughout the 297 primary and secondary treatment processes based on the CIP1 dataset. The primary process relies 298 mostly on removal of APIs through adsorption onto sludge (Stockholm Vatten, 2010) as retention 299 times are relatively low and so this fits well to the data found for OXTCY, as it is previously known 300 to adsorb strongly onto solids (Verlicchi, 2012) In the CIP2 data set (Table 5) 2) The APIs were detected at ng/l levels in a highly complex matrix (particularly the influent) 343 therefore analytical errors may lead to apparent increase in concentrations during treatment 344 (Jelic et al., 2011) . 345
3) In some cases this is a real effect, for example E1 is a degradation product of E2 (Heffley et 346 al., 2014) and so if the rate of loss of E1 during treatment is less than that of E2, then an 347 apparent increase in E1 will occur. 348 349
3.2
What is the environmental risk of the APIs being discharged in WwTW effluent?
350
The median and interquartile concentration values of pharmaceuticals in influents and effluents are 351 summarised in Table 5 . the observed concentrations in effluents to the relevant estimated PNEC. This ratio represents the 364 dilution that would be required to achieve compliance, assuming zero upstream concentrations. An 365 important proportion of UK wastewater treatment discharges are not subject to very much greater than 366 a twofold dilution so the potential for downstream non-compliance with PNEC values does exist on 367 the basis of a single effluent discharge alone. Table 3 shows that over 500 WwTW has estimated 368 dilutions of less than 2, 8% of all the WwTW in the UK. Added to this concern must be a 369 consideration of the pharmaceutical concentrations already present in a receiving watercourse 370 upstream of the discharge. Whilst the CIP2 programme did not include the determination of 371 pharmaceuticals in upstream river samples such analysis was undertaken for a range of Priority 372 Substances, including trace organic compounds that like pharmaceuticals, are primarily discharged as 373 a result of domestic inputs to wastewater. The evidence obtained from these investigations is that the 374 burden of upstream contamination is far from irrelevant and that discharges in the higher parts of a 375 river catchment, for example from septic tanks and small WwTW, can raise concentrations to values 376 that subsequent discharges lower in the catchment only serve to maintain (Phillips et al., 2015) . This 377 is an aspect that deserves careful future examination in the context of pharmaceuticals. 
390
Applying a more realistic risk assessment using estimates of available dilution for UK WwTW 391 effluents discharged to receiving waters, combined with the measured API concentrations from the 392 CIP2 dataset generates a similar priority ranking list in terms of the number of WwTW potentially 393 exceeding downstream estimated PNECs after the effluent has mixed with receiving water (Figure 5) . 394
For IBPF this equates to 890 WwTW or 13% of all WwTW in the UK. This estimate is also based on 395 the assumption that there are no significant inputs of API upstream of the WwTW in question. 
